Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract

 

 Permissions and Reprints

A 63-year-old man was admitted to our hospital with rectal bleeding. He had a history of Billroth II surgery for bleeding peptic ulcer disease 30 years ago. He had no other medical problems, and was receiving no medications. His hemoglobin level was 5.6 g/dL. Upper gastrointestinal endoscopy revealed fresh blood and clots in the residual stomach and efferent loop. A Dieulafoy lesion with spurting hemorrhage was found near the gastrojejunal anastomosis ([Fig. 1 a]).

Fig. 1 a Dieulafoy lesion with spurting hemorrhage. b Application of three clips did not result in hemostasis. Ankaferd Blood Stopper was successfully used adjunctive to hemoclipping and injection of epinephrine. c Three days later, endoscopic appearance of nonbleeding lesion.

We initially applied three hemoclips to the lesion, but as the bleeding persisted ([Fig. 1 b]), 2 mL epinephrine (1 : 10 000 dilution) was injected around the bleeding site. Mucosal oozing still continued, so 12 mL Ankaferd Blood Stopper (ABS; Ankaferd Health Products Ltd., Istanbul, Turkey) was applied topically using a disposable washing pipe.

The bleeding was observed to stop within 2 s. The patient’s hemoglobin level subsequently stabilized at 10.2 g/dL without further transfusion. Three days later, upper gastrointestinal endoscopy showed the site with hemoclips. There was no further bleeding ([Fig. 1 c]).

ABS is a unique medicinal plant extract which has been approved in the management of dental surgery bleeding and external hemorrhage in Turkey [1]. It induces very rapid formation of a unique protein network in the plasma and serum samples [1]. ABS was previously used with success in a patient with bleeding from a hepaticojejunostomy anastomosis refractory to conventional endoscopic interventions [2]. Endoscopic therapy is the “standard of care” since the success rate with endoscopically accessible Dieulafoy lesions is about 95 % [3] [4] [5]. However, it cannot always stop bleeding completely, and therefore hemorrhagic shock, circulatory failure, morbidity, and mortality are still important life-threatening problems in this clinical setting. ABS may be useful as an adjunctive agent to mechanical intervention in cases of serious arterial bleeding. Neither any local adverse effect nor systemic toxicity was observed following the topical application of ABS.

Endoscopy_UCTN_Code_TTT_1AO_2AD

References

• 1 Goker H, Haznedaroglu I C, Ercetin S. et al . Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper.  J Int Med Res. 2008;  36 163-170
  PubMedGoogle Scholar
• 2 Kurt M, Disibeyaz S, Akdogan M. et al . Endoscopic application of Ankaferd Blood Stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: A case report.  Am J Gastroenterol. 2008;  103 2156-2158
  CrossrefPubMedGoogle Scholar
• 3 Parra-Blanco A, Takahashi H, Méndez Jerez P V. et al . Endoscopic management of Dieulafoy lesions of the stomach: a case study of 26 patients.  Endoscopy. 1997;  29 834-839
  PubMedGoogle Scholar
• 4 Norton I D, Petersen B T, Sorbi D. et al . Management and long-term prognosis of Dieulafoy lesion.  Gastrointest Endosc. 1999;  50 762-767
  CrossrefPubMedGoogle Scholar
• 5 Linhares M M, Filho B H, Schraibman V. et al . Dieulafoy lesion: endoscopic and surgical management.  Surg Laparosc Endosc Percutan Tech. 2006;  16 1-3
  CrossrefPubMedGoogle Scholar

M. KurtMD 

Department of Gastroenterology, Turkiye Yuksek Ihtisas Teaching and Research Hospital

Sihhiye
Ankara
Turkey

Fax: +90-312-3124120

Email: dr.mevlutkurt@gmail.com